Drug Companies Oppose Moves to Reimburse Off-Label Medicine
AcelRx Pharmaceuticals Receives Complete Response Letter from FDA for New Drug Application for Zalviso™
Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR® (sorafenib) in Patients with Advanced Breast Cancer
MONDAY DEADLINE: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Vertex Pharmaceuticals Incorporated and Its Board of Directors and a Lead Plaintiff Deadline of July 28, 2014 -- VRTX
Bayer and Onyx Say Phase III Trial of Nexavar Breast Cancer Treatment Failed
Reckitt Benckiser Plans to Divest Its U.S. Pharma Division -- Report
Greenlight Notes Short Positions in Safeway, Lorillard -Reuters
Our most popular articles and videos for the week ended July 25.
Research and Markets: Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon
In an excerpt from their new book, Morningstar's Heather Brilliant and Elizabeth Collins explore how to identify a moat and how intangible assets can help a firm carve out a sustainable competitive advantage.